| 2004-03 |
Established Oncoris BioPharma Inc. in Minato-ku, Tokyo, with the purpose of researching and developing tumor-lysis viruses and molecular-targeted anti-tumor drugs. |
| 2004-03 |
Incorporated Oncolys BioPharma Inc. in Minato-ku, Tokyo for the research and development of oncolytic viruses and molecular targeted anti-cancer drugs |
| 2005-05 |
OBP-401 was selected for the NEDO (New Energy and Industrial Technology Development Organization) 2005 (Heisei 17) Molecular Imaging Device Research and Development Project / Malignant Tumor Treatment Support Molecular Imaging Device R&D Project grant. |
| 2005-05 |
Obtained a grant from NEDO (New Energy and Industrial Technology Development Organization) for research on OBP-401 (TelomeScan) entitled 'Molecule Imaging Device Research and Development Project/Malignant Tumor Treatment Support Molecule Imaging Device Research and Development Project' |
| 2006-03 |
Submitted an IND (Investigational New Drug) application for OBP-301 to the U.S. Food and Drug Administration (FDA). |
| 2006-03 |
Filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for OBP-301 (Telomelysin) |
| 2006-06 |
Entered an exclusive worldwide licensing agreement with Yale University (USA) for a novel HIV treatment drug and began research and development as OBP-601 (Censavudine). |
| 2006-06 |
Concluded a worldwide Exclusive License Agreement with Yale University (U.S.A.) on a new HIV drug, OBP-601(Censavudine) and started research and development on it |
| 2006-07 |
Moved headquarters to Aoba Building, 3-3 Roppongi, Minato-ku, Tokyo. |
| 2006-10 |
Established the Kyoto Research Center in Kyoto City, Kyoto Prefecture, and obtained a Japanese domestic patent (No. 3867968) for OBP-301. |
| 2006-10 |
Initiated Phase 1 clinical trials of OBP-301 in the United States. |
| 2006-10 |
Established Kyoto Research Center in Kyoto-city, Kyoto Japan Patent 3867968 of OBP-301 (Telomelysin) was issued. |
| 2006-10 |
Started Phase 1 clinical trial in the U.S. for Telomelysin |
| 2007-09 |
Received the 5th Japan Bio-Venture Award Minister of Education, Culture, Sports, Science and Technology Prize (sponsored by Fuji Sankei Business AI). |
| 2007-09 |
Received the Grand Prix of the 5th Japan Bio-Venture Award (sponsored by FujiSankei Business i) |
| 2007-11 |
Relocated the Kyoto Research Center to Kobe City, Hyogo Prefecture, becoming the Kobe Research Center. |
| 2007-11 |
Moved Kyoto Research Center to Kobe-city, Kobe, and named Kobe Research Center |
| 2008-03 |
Signed a strategic partnership agreement with Medigen Biotechnology Corp. (Taiwan) regarding OBP-301 and submitted an IND application for OBP-601 (Censavudine) to the U.S. FDA. |
| 2008-03 |
Concluded a Strategic Alliance Agreement with Medigen Biotechnology Corp. (Taiwan) for OBP-301 (Telomelysin) Filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for OBP-601(Censavudine) |
| 2008-03 |
Concluded a Strategic Alliance Agreement with Medigen Biotechnology Corp. (Taiwan) for OBP-301 (Telomelysin) |
| 2008-03 |
Filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for OBP-601(Censavudine) |
| 2008-05 |
Started Phase 1a clinical trials of OBP-601 (Censavudine) in the United States. |
| 2008-05 |
Started Phase 1a clinical trial in the U.S. for OBP-601(Censavudine) |
| 2008-08 |
Applied for approval from the French Agency for the Safety of Health Products (AFSSAPS) to conduct Phase 1b/2a clinical trials of OBP-601 (Censavudine). |
| 2008-08 |
Filed an application to start Phase 1b/2a clinical trial with French National Agency for the Safety of Health Products (AFSSAPS) for OBP-601(Censavudine) |
| 2009-01 |
Commenced Phase 1b/2a clinical trials of OBP-601 (Censavudine) in France. |
| 2009-01 |
Started Phase 1b/2a clinical trial in France for OBP-601(Censavudine) |
| 2009-09 |
U.S. patent No. 7,589,078 for OBP-601 (Censavudine) was granted. |
| 2009-09 |
U.S. Patent 7,589,078 of OBP-601(Censavudine) was issued. |
| 2009-10 |
Signed an exclusive worldwide licensing agreement with Astellas Pharma Inc. for a novel molecular-targeted anticancer drug and began research and development as OBP-801. |
| 2009-10 |
Concluded a worldwide exclusive license agreement with Astellas Pharma Inc. on a novel molecular targeting anti-cancer drug, and started research and development of OBP-801 |
| 2010-07 |
OBP-401 was selected for the NEDO (New Energy and Industrial Technology Development Organization) 2010 (Heisei 22) Innovation Utilization Development Grant. |
| 2010-07 |
Obtained a grant from NEDO for OBP-401 (TelomeScan) as Innovation Promotion Program for fiscal 2010 |
| 2011-04 |
Signed an exclusive worldwide licensing agreement with the National Institute of Advanced Industrial Science and Technology (AIST) for the novel diagnostic test OBP-1101 and began research and development. |
| 2011-04 |
Concluded an exclusive worldwide license agreement with National Institute of Biomedical Innovation for OBP-1101 (TelomeScan F35) and started research and development of OBP-1101 (TelomeScan F35) |
| 2011-11 |
Received the 2011 (Heisei 23) Deals of Distinction Award in the Industry-Government-Academia Collaboration category for the licensing of OBP-601 (Censavudine) at the annual meeting of the Licensing Executives Society of the United States and Canada. |
| 2012-03 |
Started Phase 2b clinical trial of OBP-601(Censavudine) in 94 institutions in 17 countries |
| 2012-04 |
US patent granted for OBP-301 (US Patent No. 8,163,892) |
| 2012-04 |
U.S. Patent 8,163,892 of OBP-301 (Telomelysin) was issued. |
| 2012-08 |
Signed a joint research agreement with Juntendo University using OBP-401 |
| 2012-08 |
Concluded a collaboration research agreement with Juntendo University regarding OBP-401 (TelomeScan) |
| 2012-09 |
Signed a joint research agreement with the National Hospital Organization Kure Medical Center / China Cancer Center using OBP-401 |
| 2012-09 |
Concluded a collaboration research agreement with National Hospital Organization Kure Medical Center and Chugoku Cancer Center regarding OBP-401 (TelomeScan) |
| 2012-11 |
Obtained a grant from JST (Japan Science and Technology Agency) as Feasibility Study (FS) Stage, Seeds Validation Type in Adaptable and Seamless Technology Transfer Program through Target-Driven R&D (A-Step) for OBP-401 (TelomeScan) |
| 2013-02 |
Concluded a worldwide exclusive license agreement with Geron Corporation for licensing patents concerning human telomerase specific reverse transcriptase (hTERT) promoter for diagnostic use in cancer |
| 2013-05 |
Obtained a grant from NEDO for OBP-801 as Innovation Promotion Program of Venture Support for fiscal 2010 |
| 2013-05 |
OBP-801 was selected for the NEDO (New Energy and Industrial Technology Development Organization) Innovation Practicalization Venture Support Project. |
| 2013-12 |
Oncolys BioPharma was listed on the Tokyo Stock Exchange Mothers. |
| 2013-12 |
Listed on the Tokyo Stock Exchange Mothers market. |
| 2014-05 |
OBP-801 was selected for the NEDO Innovation Practicalization Venture Support Project. |
| 2014-11 |
Started Phase 1/2 clinical trial in the Korea & Taiwan for Telomelysin |
| 2014-11 |
Phase 1/2 clinical trials of OBP-301 were initiated in Taiwan. |
| 2014-11 |
Submitted an IND (Investigational New Drug) application for OBP-801 to the U.S. Food and Drug Administration (FDA). |
| 2015-05 |
Filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for OBP-801 |
| 2015-05 |
Started Phase 1 clinical trial in the U.S. for OBP-801 |
| 2015-05 |
Started research and development of OBP-702 & OBP-405 |
| 2015-05 |
Phase 1 clinical trials of the epigenetic cancer therapeutic OBP-801 were started in the United States. |
| 2015-07 |
Commercial sales of the cancer diagnostic test OBP-401 to Deciphera Pharmaceuticals, LLC (U.S.), a company specializing in kinase inhibitor development, commenced. |
| 2015-08 |
Initiated research and development of next-generation oncolytic viruses OBP-702 and OBP-405. |
| 2015-12 |
It was decided that the cancer diagnostic test OBP-401 would be used to validate efficacy in Deciphera Pharmaceuticals, LLC (U.S.)'s anticancer drug development. |
| 2016-05 |
Completed the maximum tolerated dose administration of OBP-301 Phase 1/2 clinical trials in Taiwan and South Korea. |
| 2016-07 |
Concluded a joint research agreement with Graduate School of Medicine, Nagoya University, for Telomelysin (OBP-301) combined with checkpoint inhibitor. |
| 2016-08 |
Concluded an investigator-initiated trial agreement with National Cancer Center Hospital East for Telomelysin (OBP-301) combined with other therapies. |
| 2016-08 |
Concluded a collaboration research agreement with Kyoto Prefectural University of Medicine for OBP-801 for glaucoma surgery. |
| 2016-08 |
Submitted a protocol of Telomelysin (OBP-301) to the Food and Drug Administration (FDA), for a Phase 2 clinical trial in the United States, for melanoma. |
| 2016-08 |
Entered into a physician-led clinical trial agreement to evaluate the efficacy of combining the tumor-lysing virus OBP-301 with other therapies in patients with progressive or metastatic solid tumors, with Dr. Toshihiko Doi's research group from the Advanced Medical Care Department of the National Cancer Center Hospital East. |
| 2016-08 |
Completed the protocol submission for the US Phase 2 clinical trial of OBP-301 targeting malignant melanoma. |
| 2016-08 |
Concluded a collaboration research agreement with Kyoto Prefectural University of Medicine for OBP-801 for glaucoma surgery |
| 2016-08 |
Submitted a protocol of Telomelysin (OBP-301) to the Food and Drug Administration (FDA), for a Phase 2 clinical trial in the United States, for melanoma |
| 2016-09 |
Established Oncolys USA Inc. |
| 2016-09 |
Established the wholly-owned subsidiary Oncolys USA Inc. in Delaware, USA, to accelerate licensing agreements for pharmaceuticals and diagnostic reagents and research and development activities, and commenced operations in New Jersey. |
| 2017-03 |
Submitted CTN for Phase 1 clinical trial in combination with radiotherapy for esophageal cancer to PMDA (Pharmaceuticals and Medical Devices Agency). |
| 2017-03 |
Entered into a capital partnership agreement with US biotech venture Precision Virologics Inc., specializing in emerging infectious disease vaccine research and development. |
| 2017-03 |
Submitted CTN for Phase 1 clinical trial in combination with radiotherapy for esophageal cancer to PMDA（Pharmaceuticals and Medical Devices Agency） |
| 2017-07 |
Initiated Phase 1 clinical trial for OBP-301 (Telomelysin) in combination with radiotherapy for esophageal cancer in Japan. |
| 2017-07 |
Patent registration of OBP-1101 in the United States. |
| 2017-07 |
Initiated dosing for the Phase 1 trial of OBP-301 combined with radiation therapy in esophageal cancer (Japan). |
| 2017-07 |
Initiated dosing for the Phase 2 trial of OBP-301 targeting melanoma (United States). |
| 2017-07 |
Initiated Phase 1 clinical trial for OBP-301 (Telomelysin) in combination with radiotherapy for esophageal cancer in Japan |
| 2017-08 |
Patent granted for OBP-1101 in China. |
| 2017-08 |
Patent granted for the substance patent of OBP-601 in Europe. |
| 2017-11 |
Entered into a joint research agreement with Juntendo University for circulating tumor cells (CTC) toward the commercialization of OBP-401/OBP-1101. |
| 2017-12 |
Started investigator-initiated clinical trial for OBP-301 (Telomelysin) in combination with pembrolizumab, an anti-PD-1 antibody in Japan. |
| 2017-12 |
Initiated dosing for the Phase 1 trial primarily targeting esophageal cancer, combining OBP-301 with the anti-PD-1 antibody pembrolizumab (Japan). |
| 2017-12 |
Started investigator-initiated clinical trial for OBP-301 (Telomelysin) in combination with pembrolizumab, an anti-PD-1 antibody in Japan |
| 2018-02 |
Patent granted for OBP-1101 in Europe. |
| 2018-05 |
Entered into a worldwide license agreement with UK-based Stabilitech for the virus preservation stabilizer patent. |
| 2019-04 |
Received "SAKIGAKE designation" on OBP-301 (Telomelysin) by Ministry of Health, Labour and Welfare. |
| 2019-04 |
OBP-301 designated as a subject item under the Ministry of Health, Labour and Welfare's 'Accelerated Review Designation' system. |
| 2019-04 |
Entered into an exclusive license and option agreement for OBP-301 in Japan and Taiwan with Chugai Pharmaceutical Co., Ltd. |
| 2019-04 |
Received "SAKIGAKE designation" on OBP-301 (Telomelysin) by Ministry of Health, Labour and Welfare |
| 2019-05 |
Initiated dosing for the Phase 2 trial primarily focused on gastric cancer and others, combining OBP-301 with anti-PD-1 antibody pembrolizumab (United States). |
| 2019-12 |
Chugai Pharmaceutical achieved the first milestone under the OBP-301 license agreement. |
| 2020-03 |
Initiated Phase 2 clinical trial for OBP-301 (Telomelysin) in combination with radiotherapy for esophageal cancer in Japan. |
| 2020-03 |
Chugai Pharmaceutical initiated dosing for the Phase 2 clinical trial of OBP-301 combined with radiation therapy in esophageal cancer (Japan). |
| 2020-03 |
Established the wholly-owned subsidiary OPA Therapeutics Inc. in California, USA. |
| 2020-03 |
Initiated Phase 2 clinical trial for OBP-301 (Telomelysin) in combination with radiotherapy for esophageal cancer in Japan |
| 2020-06 |
Received Orphan Drug Designation from the US FDA for OBP-301 as a treatment for esophageal cancer. |
| 2020-06 |
Concluded a worldwide Exclusive License Agreement with Transposon Therapeutics, Inc (U.S.A.) on the nucleoside reverse transcriptase inhibitor (NRTI) OBP-601 (censavudine). |
| 2020-06 |
The U.S. Food and Drug Administration designated OBP-301 as an orphan drug. |
| 2020-06 |
Transposon Therapeutics, Inc. (USA) entered into a worldwide exclusive license agreement for OBP-601. |
| 2020-06 |
Signed a patent assignment agreement with Kagoshima University and began development of a novel coronavirus treatment. |
| 2020-06 |
Received Orphan Drug Designation from the US FDA for OBP-301 as a treatment for esophageal cancer |
| 2020-06 |
Concluded a worldwide Exclusive License Agreement with Transposon Therapeutics, Inc (U.S.A.) on the nucleoside reverse transcriptase inhibitor (NRTI) OBP-601 (censavudine) |
| 2020-11 |
Transposon achieved the first milestone under the OBP-601 license agreement. |
| 2021-02 |
Been selected "suratanodeturev" for OBP-301 (Telomelysin) by International Nonproprietary Names (INN) Expert Committee of the WHO. |
| 2021-02 |
The World Health Organization (WHO) designated the international nonproprietary name of OBP-301 as suratadenoturev. |
| 2021-02 |
Been selected “suratanodeturev” for OBP-301 (Telomelysin) by International Nonproprietary Names (INN) Expert Committee of the WHO |
| 2021-11 |
Transposon commenced dosing in a Phase 2 clinical trial (USA) for OBP-601 targeting progressive supranuclear palsy (PSP). |
| 2022-01 |
Transposon began dosing in a Phase 2a clinical trial (USA) for OBP-601 targeting amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). |
| 2022-04 |
Listed on the Tokyo Stock Exchange Growth Market. |
| 2022-08 |
Transposon completed enrollment of patients in the Phase 2 clinical trial for OBP-601 targeting progressive supranuclear palsy (PSP). |
| 2022-12 |
Achieved the last patient enrollment in Phase 2 pivotal clinical trial for OBP-301 (Telomelysin) in combination with radiotherapy for esophageal cancer in Japan. |
| 2022-12 |
Completed final enrollment in the Phase 2 clinical trial of OBP-301 combined with radiation for esophageal cancer. |
| 2022-12 |
Achieved the last patient enrollment in Phase 2 pivotal clinical trial for OBP-301 (Telomelysin) in combination with radiotherapy for esophageal cancer in Japan |
| 2023-06 |
Made an announcement of the results from an investigator-initiated phase 2 clinical trial for OBP-301 (Telomelysin) in combination with pembrolizumab in advanced gastric and gastroesophageal junction (GEA) adenocarcinoma at ASCO 2023. |
| 2023-06 |
Presented results of the Phase 2 clinical trial of OBP-301 combined with pembrolizumab for gastric cancer at ASCO 2023. |
| 2023-06 |
Made an announcement of the results from an investigator-initiated phase 2 clinical trial for OBP-301 (Telomelysin) in combination with pembrolizumab in advanced gastric and gastroesophageal junction (GEA) adenocarcinoma at ASCO 2023 |
| 2024-02 |
Signed a sales partnership agreement in Japan for OBP-301 with Fujifilm Toyama Chemical. |
| 2024-05 |
OBP-601 was designated for Fast Track status for progressive supranuclear palsy (PSP). |
| 2025-03 |
Initiated a pre-IND comprehensive evaluation consultation for OBP-301. |
| 2025-04 |
Obtained a manufacturing and sales license for regenerative medicine products. |
| 2025-12 |
OBP-301 was designated as a regenerative medicine product for rare diseases. |
| 2025-12 |
Filed a manufacturing and sales approval application for OBP-301. |
| 2026-06 |
Obtained standard approval for manufacturing and sales of the oncolytic virus telomelysin injection. |
